BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical is a U.S. biotechnology company focused on medicines for rare and genetically defined conditions. It develops, manufactures and commercializes therapies informed by genetic and disease biology, including enzyme-based and other targeted treatment approaches. The company is based in San Rafael, California, and its shares are traded on Nasdaq under BMRN. BioMarin's long-term focus includes skeletal and metabolic conditions as well as other rare disorders where specialized drug development and manufacturing capabilities are important.
Company at a glance
Corporate information
- Company entity
- BioMarin Pharmaceutical Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.biomarin.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: BMRN
genetic medicines · enzyme therapies · targeted therapeutics
rare genetic diseases · skeletal conditions · metabolic disorders
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
BioMarin Pharmaceutical is a U.S. biotechnology company focused on medicines for rare and genetically defined conditions. It develops, manufactures and commercializes therapies informed by genetic and disease biology, including enzyme-based and other targeted treatment approaches. The company is based in San Rafael, California, and its shares are traded on Nasdaq under BMRN. BioMarin's long-term focus includes skeletal and metabolic conditions as well as other rare disorders where specialized drug development and manufacturing capabilities are important.
Business, technology & evidence
- SecuritiesNasdaq: BMRN
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · BioMarin Pharmaceutical Inc. ↗BioMarin Pharmaceutical Inc. ·
- Official issuer and R&D disclosure · BioMarin Pharmaceutical Inc. ↗BioMarin Pharmaceutical Inc. ·
- Official issuer and R&D disclosure · BioMarin Pharmaceutical Inc. ↗BioMarin Pharmaceutical Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.